The problem
Developing an antibody drug means hunting through millions of immune cells for the rare antibody that binds exactly the right disease target — then engineering it into a safe, manufacturable medicine. The process normally takes years and demands microfluidics, AI screening, and manufacturing that few biotechs own end to end.
How it works
AbCellera runs an integrated engine from target identification through to clinical manufacturing. It screens natural immune responses for binders, optimizes candidates on platforms such as its multispecific T-cell engager (TCE) system, and hands pharma partners development-ready antibodies — while advancing its own programs in endocrinology, women’s health, immunology, and oncology. Founder and CEO Carl Hansen started the company in 2012 out of his University of British Columbia lab, and at the pandemic’s outset it moved from screening blood samples to human trials of a COVID-19 antibody in 90 days.
Pain points
Discovery timelines measured in years, hit-finding that needs rare instrumentation and compute, and small drug developers with no path from a lab hit to a clinical-grade manufactured candidate.
Business model
Partner-funded discovery economics: upfront cash per program, option fees to take candidates forward, milestone payments, and tiered sales royalties — plus the upside of AbCellera’s wholly owned clinical pipeline. The June 2026 Jazz collaboration follows this template: $56M upfront for two programs ($28M more for a third) and up to $792M per program in milestones and royalties.
Challenges
COVID-19 royalties from bamlanivimab (partnered with Eli Lilly, authorized by the FDA and Health Canada) faded as the pandemic receded, and the shares fell far below their first-day peak — so AbCellera must now prove the engine earns recurring non-COVID income through deals like Jazz and Vertex and its own menopause and oncology readouts.
Funding
- Raised: US$555.5M in a December 2020 Nasdaq IPO (ABCL) — the largest biotech IPO in Canadian history (Bloom Burton).
- Valuation: MISSING.
Latest — June 2026
Jazz Pharmaceuticals agreed to pay AbCellera $56M upfront (plus $28M for a third program) with up to $792M per program in option and milestone payments — up to ~$2.46B total — to discover next-generation T-cell engagers for gastrointestinal and other hard-to-treat solid tumors (BioSpace, June 17, 2026).